Big pharma companies are struggling to develop treatments for "long COVID" because it's been nearly impossible to nail down what exactly the ailment actually is.
The New York Times' David Leonhardt broke down the evidence Tuesday and concluded that mask mandate policy has a negligible impact on COVID-19 caseloads.